NCT07040332 Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis
| NCT ID | NCT07040332 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Qianfoshan Hospital |
| Condition | Allergic Bronchopulmonary Aspergillosis (ABPA) |
| Study Type | OBSERVATIONAL |
| Enrollment | 140 participants |
| Start Date | 2025-05-10 |
| Primary Completion | 2027-07-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 140 participants in total. It began in 2025-05-10 with a primary completion date of 2027-07-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to reveal the immune and inflammatory regulatory molecular mechanisms related to the progression of allergic bronchopulmonary aspergillosis (ABPA), and to build a precision typing based on inflammation and identify the biomarkers of typing, and to explore the clinical outcomes of different inflammatory phenotypes.
Eligibility Criteria
Inclusion Criteria: * Meets the diagnostic criteria for allergic bronchopulmonary aspergillosis. * Meets the diagnostic criteria for fungal-sensitized asthma. Exclusion Criteria: * Human immunodeficiency virus infection. * Malignant tumor. * Blood system disease. * autoimmune system disease. * History of pulmonary tuberculosis. * Patients with a history of smoking or still smoking. * Invasive pulmonary fungal disease. * Contraindications electronic bronchoscopy
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07040332 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Allergic Bronchopulmonary Aspergillosis (ABPA). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07040332 currently recruiting?
Yes, NCT07040332 is actively recruiting participants. Contact the research team at qiqianqlh@163.com for enrollment information.
Where is the NCT07040332 trial being conducted?
This trial is being conducted at Jinan, China.
Who is sponsoring the NCT07040332 clinical trial?
NCT07040332 is sponsored by Qianfoshan Hospital. The trial plans to enroll 140 participants.